The role of immunohistochemistry in dermatopathology: Applications and challenges.

Henry Jagdeo*

Department of Dermatology, University of New South Wales, Australia

Introduction

Immunohistochemistry (IHC) has revolutionized dermatopathology by enhancing the accuracy of diagnosing various skin diseases, particularly neoplastic and inflammatory conditions. By utilizing specific antibodies to detect proteins in tissue sections, IHC provides valuable insights into the molecular and cellular characteristics of skin lesions. This technique is indispensable for differentiating between benign and malignant tumors, classifying lymphomas, and identifying infectious agents in dermatological specimens [1].

IHC is a staining method that relies on antigen-antibody interactions to detect specific proteins within tissue samples. The process involves applying primary antibodies against target antigens, followed by secondary antibodies conjugated to a chromogen, which produces a visible color reaction. This enables pathologists to visualize the distribution and intensity of protein expression under a microscope, providing crucial diagnostic and prognostic information [2].

One of the most significant applications of IHC in dermatopathology is in the diagnosis of skin malignancies. It helps differentiate between morphologically similar tumors, such as distinguishing basal cell carcinoma (BCC) from squamous cell carcinoma (SCC). Markers like Ber-EP4 are commonly used to identify BCC, while SCC expresses cytokeratin 5/6 and p63. Additionally, IHC is vital for diagnosing melanocytic lesions by differentiating benign nevi from malignant melanoma using markers like S100, HMB-45, and Melan-A [3].

Cutaneous lymphomas can be challenging to diagnose due to their histological overlap with inflammatory dermatoses. IHC aids in subclassifying lymphomas by identifying lineage-specific markers. For instance, mycosis fungoides, a type of cutaneous T-cell lymphoma, typically expresses CD3 and CD4, while cutaneous B-cell lymphomas express CD20 and PAX5. These markers help distinguish between reactive and neoplastic lymphoproliferative disorders, ensuring accurate diagnosis and appropriate treatment [4].

Beyond neoplastic conditions, IHC plays a role in diagnosing inflammatory and autoimmune skin disorders. For example, direct immunofluorescence (DIF), a variant of IHC, is essential for detecting immune complex deposition in conditions like lupus erythematosus and pemphigus vulgaris. DIF can identify characteristic immunoglobulin and complement deposits at the dermoepidermal junction or within epidermal keratinocytes, guiding the diagnosis of immune-mediated diseases [5].

IHC is also used to detect pathogens in cutaneous infections. It can identify viral, bacterial, and fungal antigens that are difficult to visualize with routine histology. For example, IHC can detect human papillomavirus (HPV) proteins in cutaneous warts and herpes simplex virus (HSV) in vesicular lesions. Similarly, it aids in diagnosing leprosy and deep fungal infections by highlighting specific microbial antigens within tissue sections [6].

In addition to aiding in diagnosis, IHC provides prognostic information that influences treatment decisions. For instance, the expression of Ki-67, a proliferation marker, helps assess the aggressiveness of melanomas and cutaneous lymphomas. Similarly, programmed death-ligand 1 (PD-L1) expression in skin cancers may predict response to immune checkpoint inhibitors, guiding personalized therapy approaches [7].

Despite its advantages, IHC has certain limitations. One major challenge is the potential for false-positive or false-negative results due to variations in antigen retrieval, antibody specificity, and tissue processing. Standardization of protocols and proper quality control measures are crucial to ensure reliable results. Additionally, IHC interpretation requires expertise, as staining patterns can be influenced by tissue fixation, background staining, and cross-reactivity with unrelated proteins [8].

The cost of IHC can be a barrier, particularly in resource-limited settings. High-quality antibodies and specialized equipment are necessary for optimal staining and interpretation. Furthermore, the need for skilled pathologists to analyze results adds to the overall expense. Efforts to develop cost-effective alternatives and automated IHC platforms may improve accessibility in under-resourced regions [9].

Advancements in IHC technology continue to refine its applications in dermatopathology. Multiplex IHC, which allows for the simultaneous detection of multiple markers, enhances diagnostic precision. Additionally, digital pathology and artificial intelligence (AI)-based image analysis are being integrated into dermatopathology workflows, enabling automated interpretation and reducing diagnostic variability. These innovations hold promise for improving the efficiency and accuracy of skin disease diagnosis [10].

***Correspondence to:** Henry Jagdeo, Department of Dermatology, University of New South Wales, Australia, E-mail: h.jagdeo@unsw.edu.au

***Received:** 1-Mar-2025, Manuscript No. aarcd-25-162359; **Editor assigned:** 4-Mar-2025, PreQC No. aarcd-25-162359 (PQ); **Reviewed:** 17-Mar-2025, QC No. aarcd-25-162359; **Revised**: 24-Mar-2025, Manuscript No. aarcd-25-162359 (R); **Published**: 31-Mar-2025, DOI:10.35841/aarcd-8.2.255.*

***Citation:** Jagdeo H. The role of immunohistochemistry in dermatopathology: Applications and challenges. Res Clin Dermatol. 2025;8(2):255.*

Conclusion

Immunohistochemistry is an essential tool in dermatopathology, providing critical insights into the diagnosis, classification, and prognosis of various skin diseases. Its applications in distinguishing neoplastic, inflammatory, and infectious conditions make it invaluable for modern dermatopathologists. However, challenges such as technical variability, cost, and the need for specialized expertise must be addressed to maximize its clinical utility. With ongoing advancements in IHC techniques and digital pathology, the future of dermatopathology is poised for greater precision and accessibility.

References

1. Compton LA, Murphy GF, Lian CG. Diagnostic immunohistochemistry in cutaneous neoplasia: An update. Dermpath. 2015;2(1):15-42.
2. Ivan D, Prieto VG. Use of immunohistochemistry in the diagnosis of melanocytic lesions: Applications and pitfalls. Future Oncol. 2010;6(7):1163-75.
3. Dewar R, Andea AA, Guitart J, et al. Best practices in diagnostic immunohistochemistry: Workup of cutaneous lymphoid lesions in the diagnosis of primary cutaneous lymphoma. Arch Pathol Lab Med. 2015;139(3):338-50.
4. Van Herck Y, Antoranz A, Andhari MD, et al. Multiplexed immunohistochemistry and digital pathology as the foundation for next-generation pathology in melanoma: Methodological comparison and future clinical applications. Front oncol. 2021;11:636681.
5. Ferringer T. Immunohistochemistry in dermatopathology. Arch Pathol Lab Med. 2015;139(1):83-105.
6. Villani AP, Chouvet B, Kanitakis J. Application of C4d immunohistochemistry on routinely processed tissue sections for the diagnosis of autoimmune bullous dermatoses. Am J Dermatopathol. 2016;38(3):186-8.
7. Ricci C, Dika E, Ambrosi F, et al. Cutaneous melanomas: A single center experience on the usage of immunohistochemistry applied for the diagnosis. Int J Mol Sci. 2022;23(11):5911.
8. Prieto VG, Shea CR. Use of immunohistochemistry in melanocytic lesions. J Cutan Pathol. 2008;35:1-0.
9. Molina-Ruiz AM, Santonja C, Rütten A, et al. Immunohistochemistry in the diagnosis of cutaneous viral infections—part I. Cutaneous viral infections by herpesviruses and papillomaviruses. Am J Dermatopathol. 2015;37(1):1-4.
10. Affolter VK. Dermatopathology–the link between ancillary techniques and clinical lesions. Vet Dermatol. 2017;8:149-62.

Citation: *Jagdeo H. The role of immunohistochemistry in dermatopathology: Applications and challenges. Res Clin Dermatol. 2025;8(2):255.*